Nat Commun
. 2021 Sep 7;12(1):5325. doi: 10.1038/s41467-021-25623-2.
Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression
Sakshi Goel 1, Vipul Bhatia 1, Sushmita Kundu 1, Tanay Biswas 1, Shannon Carskadon 2, Nilesh Gupta 3, Mohammad Asim 4, Colm Morrissey 5, Nallasivam Palanisamy 2, Bushra Ateeq 6 7
Affiliations
1Molecular Oncology Laboratory, Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, U.P., India.
2Vattikuti Urology Institute, Department of Urology, Henry Ford Health System, Detroit, MI, USA.
3Department of Pathology, Henry Ford Health System, Detroit, MI, USA.
4Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
5Department of Urology, University of Washington, Seattle, WA, USA.
6Molecular Oncology Laboratory, Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, U.P., India. bushra@iitk.ac.in.
7The Mehta Family Center for Engineering in Medicine, Indian Institute of Technology Kanpur, Kanpur, U.P., India. bushra@iitk.ac.in.
PMID: 34493733 DOI: 10.1038/s41467-021-25623-2
Free article
Abstract
Distal-less homeobox-1 (DLX1) is a well-established non-invasive biomarker for prostate cancer (PCa) diagnosis, however, its mechanistic underpinnings in disease pathobiology are not known. Here, we reveal the oncogenic role of DLX1 and show that abrogating its function leads to reduced tumorigenesis and metastases. We observed that ~60% of advanced-stage and metastatic patients display higher DLX1 levels. Moreover, ~96% of TMPRSS2-ERG fusion-positive and ~70% of androgen receptor (AR)-positive patients show elevated DLX1, associated with aggressive disease and poor survival. Mechanistically, ERG coordinates with enhancer-bound AR and FOXA1 to drive transcriptional upregulation of DLX1 in ERG-positive background. However, in ERG-negative context, AR/AR-V7 and FOXA1 suffice to upregulate DLX1. Notably, inhibiting ERG/AR-mediated DLX1 transcription using BET inhibitor (BETi) or/and anti-androgen drugs reduce its expression and downstream oncogenic effects. Conclusively, this study establishes DLX1 as a direct-target of ERG/AR with an oncogenic role and demonstrates the clinical significance of BETi and anti-androgens for DLX1-positive patients.
